Empress Looks To The Body’s Internal Chemistry For Drug Leads

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Emerge
Empress uses its Chemilogics platform for quick drug leads in multiple therapeutic areas • Source: Shutterstock

Empress Therapeutics CEO Jason Park explains his company’s approach to drug discovery and development as “bringing a genetic basis to small molecule drugs.” When the Cambridge, MA-based firm emerged from stealth last June with $50m in funding from Flagship Pioneering, Empress said it had already developed 15 drug leads from its Chemilogics platform that harnesses artificial intelligence and machine learning to model natural processes in the human body that might offer a guide to producing drugs.

Empress Therapeutics at a glance

  • Location: Cambridge, MA

When Scrip spoke with Park, he said that in less than a year, the company that he also co-founded has...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Emerging Company Profiles

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Empress Looks To The Body’s Internal Chemistry For Drug Leads

 
• By Joseph Haas

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Mythic Therapeutics Faces An Acid Test

 
• By Elizabeth Cairns

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.    

Emergex Goes To Battle Against ‘The Nasties’

 
• By Alaric DeArment

Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.

More from Start-Ups & SMEs

Pathalys Raises $105m To Pave Path Toward US Commercialization

 
• By Mandy Jackson

The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.

Empress Looks To The Body’s Internal Chemistry For Drug Leads

 
• By Joseph Haas

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown

 
• By Alaric DeArment

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.